Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial  

作　　者：Domina Kekez Juraj Prejac Gordan Adzic Niksa Librenjak Irma Gorsic Danijela Jonjic Zeljko Krznaric Goran Augustin Stjepko Plestina 

机构地区：[1]Department of Oncology,University Hospital Centre Zagreb,Zagreb 10000,Grad Zagreb,Croatia [2]School of Dental Medicine,University of Zagreb,Zagreb 10000,Grad Zagreb,Croatia [3]Department of Internal Medicine,University Hospital Centre Zagreb,Zagreb 10000,Grad Zagreb,Croatia [4]School of Medicine,University of Zagreb,Zagreb 10000,Grad Zagreb,Croatia [5]Department of Surgery,University Hospital Centre Zagreb,Zagreb 10000,Grad Zagreb,Croatia

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期264-273,共10页世界胃肠肿瘤学杂志(英文)

摘　　要：BACKGROUND Colorectal cancer(CRC)represents a major global public health issue,ranking as the third most common cancer worldwide.Given the substantial prevalence of CRC,there is a critical need to identify precise prognostic and predictive biomar-ker tools for better treatment outcomes.Phase angle(PA)has been proposed as a prognostic marker in various non-malignant and malignant clinical conditions.AIM To investigate the relationship between PA and survival outcomes in the first-line treatment of metastatic CRC(mCRC).METHODS In this prospective observational study,we obtained data on patients who started first-line systemic chemotherapy from the beginning of 2020 until the end of 2022.The PA,assessed by the bioelectrical impedance analysis scale,was evaluated as a possible prognostic factor for treatment outcomes,which were measured as pro-gression-free survival(PFS)and objective response rate(ORR).RESULTS Using the cut-point value for PA set at 4.60°,144 patients were divided into two cohorts.The high PA group of patients exhibited a significantly longer median PFS than the low PA group,14.8 vs 10.5 months,respectively.No difference in ORR was observed.However,patients with PA≥4.60°had a higher disease control rate.CONCLUSION PA represents a novel and objective pre-chemotherapy prognostic factor to identify mCRC patients who are at increased risk of a worse survival outcome.

关 键 词：Phase angle Bioimpedance scale Metastatic colorectal cancer Treatment outcomes First-line chemotherapy 

分 类 号：R73[医药卫生—肿瘤]